1) Unwin N. Acetylcholine receptor channel imaged in the open state. Nature 1995;373:37-43.
Clear Q&A 88 筋弛緩薬を知りつくす 改訂第2版
商品紹介
大好評書“Clear Q&A 75”の改訂第2版が完成！ 難解な神経生理や拮抗薬の作用特徴、そして臨床麻酔に有用なかつ信頼できる筋弛緩モニタリングのコツとポイントなどを薬理編：60問／モニター編：28問に厳選しました。第一線で活躍する麻酔科医の日々の臨床知見の幅が、さらに広がる内容を取り上げました。怒濤の88問をご堪能ください
目次
- I 薬理編
Q1 神経筋の化学的伝達とは、どういうこと？
Q2 興奮収縮連関とは？
Q3 安全域とは？
Q4 筋弛緩薬は受容体にどのように結合するの？
Q5 筋弛緩薬は終板の受容体以外にも作用するの？
Q6 脱感作性ブロックやオープンチャネルブロックとは、どんなブロック？
Q7 Respiratory sparing effectとは、どんな効果？
Q8 末梢性筋弛緩薬は中枢神経系への作用はあるの？
Q9 筋弛緩薬は飲んでも効くの？
Q10 ロクロニウムの血管外漏出が起きたときには、どうしたらいいの？
Q11 低力価の筋弛緩薬のほうが、速く効き出すのはなぜ？
Q12 ロクロニウムの作用発現は、循環状態に影響されるの？
Q13 プライミングテクニックと、プレキュラリゼーションとは？
Q14 タイミングプリンシプルとは？
Q15 麻酔導入時、マスク換気ができない場合に筋弛緩薬を投与するの？
ほか
II モニター編
Q61 利き腕と逆の腕、モニターはどちらに付けるの？
Q62 電極の貼り方は？
Q63 なぜ、2Hz-TOF刺激が用いられるの？
Q64 適切な神経刺激の大きさは？
Q65 TOFウォッチのキャリブレーションとは？
Q66 刺激の矩形波とか、パルス幅ってなに？
Q67 刺激が出来ない場合の対処は？
Q68 刺激されているのにTOF比が表示されないのは？
Q69 反応値がばらつく場合の対処法は？
Q70 Direct stimulationとは、どのような状態なの？
Q71 Staircase phenomenonとは、どのような現象なの？
Q72 TOF比のノーマリゼーションとは、どういう意味？
Q73 TOFウォッチに皮膚温計が付いている理由は？
Q75 筋弛緩薬の薬力学的評価のための測定項目は？
ほか
この書籍の参考文献
参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。
本参考文献は電子書籍掲載内容を元にしております。
I 薬理編
P.4 掲載の参考文献
P.9 掲載の参考文献
1) Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972;37:417-22.
P.11 掲載の参考文献
1) Liu M, Dilger JP. Site selectivity of competitive antagonists for the mouse adult muscle nicotinic acetylcholine receptor. Mol Pharmacol 2009;75:166-73.
2) Liu M, Dilger JP. Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg 2008;107:525-33.
3) Dilger JP, Vidal AM, Liu M, et al. Roles of amino acids and subunits in determining the inhibition of nicotinic acetylcholine receptors by competitive antagonists. Anesthesiology 2007;106:1186-95.
P.14 掲載の参考文献
1) Bowman WC, Prior C, Marshall IG. Presynaptic receptors in the neuromuscular junction. Ann NY Acad Sci 1990;604:69-81.
2) Gibb AJ, Marshall IG. Examination of the mechanisms involved in tetanic fade produced by vecuronium and related analogues in the rat diaphragm. Br J Pharmacol 1987;90:511-21.
P.20 掲載の参考文献
P.22 掲載の参考文献
1) Fuchs-Buder T, Strowitzki M, Rentsch K, et al. Concentration of rocuronium in cerebrospinal fluid of patients undergoing cerebral aneurysm clipping. Br J Anaesth 2004;92:419-21.
2) Chiodini FC, Tassonyi E, Fuchs-Buder T, et al. Effects of neuromuscular blocking agents on excitatory transmission and γ-aminobutyric acidA-mediated inhibition in the rat hippocampal slice. Anesthesiology 1998;88:1003-13.
3) Cardone C, Szenohradszky J, Yost S, et al. Activation of brain acetylcholine receptors by neuromuscular blocking drugs. A possible mechanism of neurotoxicity. Anesthesiology 1994;80:1155-61.
4) Cesur M, Alici HA, Erdem AF, et al. Accidental caudal injection of rocuronium in an awake patient. Anesthesiology 2005;103:444-5.
5) Pudeto VA, Gungui P, Di Martino MR, et al. Accidental subarachnoid injection of pancuronium. Anesth Analg 1989;69:516-7.
6) Howell S, Driver RP. Unintentional intracerebroventricular administration of etomidate and rocuronium. Anesth Analg 2008;106:520-2.
7) Minton MD, Grosslight K, Stirt JA, et al. Increases in intracranial pressure from succinylcholine:Prevention by prior nondepolarizing blockade. Anesthesiology 1986;65:165-9.
8) Messner M, Beese U, Romstock J, et al. The bispectral index declines during neuromuscular block in fully awake persons. Anesth Analg 2003;97:488-91.
P.26 掲載の参考文献
1) Iwasaki H, Namiki A, Omote T, et al. Neuromuscular effects of subcutaneous administration of pancuronium. Anesthesiology 1992;76:1049-51.
P.29 掲載の参考文献
1) Ezri T, Szmuk P, Warters RD, et al. Changes in onset time of rocuronium in patients pretreated with ephedrine and esmolol-The role of cardiac output. Acta Anaesthesiol Scand 2003;47:1067-72.
P.31 掲載の参考文献
1) Shiraishi N, Aono M, Kameyama Y, et al. Effects of cardiac output on the onset of rocuroniuminduced neuromuscular block in elderly patients. J Anesth 2018;32:547-50.
2) Ezri T, Szmuk P, Warters RD, et al. Changes in onset time of rocuronium in patients pretreated with ephedrine and esmolol-The role of cardiac output. Acta Anaesthesiol Scand 2003;47:1067-72.
3) Ishigaki S, Masui K, Kazama T. Saline flush after rocuronium bolus reduces onset time and prolongs duration of effect:A randomized clinical trial. Anesth Analg 2016;122:706-11.
4) Yoshida F, Suzuki T, Kashiwai A, et al. Correlation between cardiac output and reversibility of rocuronium-induced moderate neuromuscular block with sugammadex. Acta Anaesthesiol Scand 2012;56:83-7.
P.34 掲載の参考文献
1) Schmidt J, Irouschek A, Muenster T, et al. A priming technique accelerates onset of neuromuscular blockade at the laryngeal adductor muscles. Can J Anesth 2005;52:50-4.
2) Fukano N, Suzuki T, Ishikawa K, et al. A randomized trial to identify optimal precurarizing dose of rocuronium to avoid precurarization-induced neuromuscular block. J Anesth 2011;25:200-4.
P.38 掲載の参考文献
P.40 掲載の参考文献
1) Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II:The Stockholm revision. Acta Anaesthesiol Scand 2007;51:789-808.
2) Mencke T, Echternach M, Kleinschmidt S, et al. Laryngeal morbidity and quality of tracheal intubation:A randomized controlled trial. Anesthesiology 2003;98:1049-56.
P.43 掲載の参考文献
1) De Jong RH. Controlled relaxation. I. Quantitation of electromyogram with abdominal relaxation. JAMA 1966;197:393-5.
2) Kirov K, Motamed C, Ndoko SK, et al. TOF count at corrugator supercilii reflects abdominal muscles relaxation better than at adductor pollicis. Br J Anaesth 2007;98:611-4.
3) Fink H, Luppa P, Mayer B, et al. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors. Anesthesiology 2003;98:82-8.
P.46 掲載の参考文献
1) Martini CH, Boon M, Bevers RF, et al. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth 2013;112:498-505.
2) Kim MH, Lee KY, Lee KY, et al. Maintaining optimal surgical conditions with low insufflation pressures is possible with deep neuromuscular blockade during laparoscopic colorectal surgery:A prospective, randomized, double-blind, parallel-group clinical trial. Medicine (Baltimore) 2016;95:e2920.
3) Madsen MV, Istre O, Staehr-Rye AK, et al. Postoperative shoulder pain after laparoscopic hysterectomy with deep neuromuscular blockade and low-pressure pneumoperitoneum:A randomised controlled trial. Eur J Anaesthesiol 2015;33:341-7.
4) Kim HJ, Lee K, Park WK, et al. Deep neuromuscular block improves the surgical conditions for laryngeal microsurgery. Br J Anaesth 2015;115:867-72.
P.49 掲載の参考文献
1) Han TH, Kim H, Bae JY, et al. Neuromuscular pharmacodynamics of rocuronium in patients with major burns. Anesth Analg 2004;99:386-92.
2) Soriano SG, Kaus SJ, Sullivan LJ, et al. Onset and duration of action of rocuronium in children receiving chronic anticonvulsant therapy. Paediatr Anaesth 2000;10:133-6.
P.51 掲載の参考文献
1) Xue FS, Tong SY, Liao X, et al. Dose-response and time-course of effect of rocuronium in male and female anesthetized patients. Anesth Analg 1997;85:667-71.
2) Adamus M, Koutna J, Gabrhelik T, et al. Influence of gender on the onset and duration of rocuronium-induced neuromuscular block. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151:301-5.
3) Dahaba AA, Perelman SI, Moskowitz DM, et al. Geographic regional differences in rocuronium bromide dose-response relation and time course of action. An overlooked factor in determining recommended dosage. Anesthesiology 2006;104:950-3.
P.53 掲載の参考文献
1) Furuya T, Suzuki T, Kashiwai A, et al. The effects of age on maintenance of intense neuromuscular block with rocuronium. Acta Anaesthesiol Scand 2012;56:236-9.
2) Yamamoto S, Yamamoto Y, Kitajima O, et al. Reversal of neuromuscular block with sugammadex:A comparison of the corrugator supercilii and adductor pollicis muscles in a randomized doseresponse study. Acta Anaesthesiol Scand 2015;59:892-901.
3) Suzuki T, Kitajima O, Ueda K, et al. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br J Anaesth 2011;106:823-6.
P.56 掲載の参考文献
1) Taivainen T, Meretoja OA, Erkola O, et al. Rocuronium in infants, children and adults during balanced anesthesia. Paediatr Anaesth 1996;6:271-5.
2) Meakin G, McKiernan EP, Morris P, et al. Dose-response curves for suxamethonium in neonates, infants and children. Br J Anaesth 1989;62:655-8.
3) Driessen JJ, Robertson EN, Van Egmond J, et al. The time-course of action and recovery of rocuronium 0.3mg × kg-1 in infants and children during halothane anaesthesia measured with acceleromyography. Paediatr Anaesth 2000;10:493-7.
4) Matsui M, Konishi J, Suzuki T, et al. Reversibility of rocuronium-induced deep neuromuscular block with sugammadex in infants and children-A randomized study. Biol Pharm Bull 2019;42:1637-40.
P.59 掲載の参考文献
1) Leykin Y, Pellis T, Lucca M, et al. The pharmacodynamics effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg 2004;99:1086-9.
2) Lemmens HJM, Brodsky JB. The dose of succinylcholine in morbid obesity. Anesth Analg 2006;102:438-42.
3) Lancker PV, Dillemans B, Bogaert T, et al. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia 2011;66:721-5.
4) Corre FL, Nejmeddine S, Fatahine C, et al. Recurarization after sugammadex reversal in an obese patient. Can J Anesth 2011;58:944-7.
P.61 掲載の参考文献
1) P5hringer FK, Sparr HJ, Mitterschiffthaler G, et al. Extended duration of action of rocuronium in postpartum patients. Anesth Analg 1997;84:352-4.
2) Camp CE, Tessem J, Adenwala J, et al. Vecuronium and prolonged neuromuscular blockade in postpartum patients. Anesthesiology 1987;67:1006-8.
3) Williamsom RM, Mallaiah S, Barclay P. Rocuronium and sugammadex for rapid sequence induction of obstetric general anaesthesia. Acta Anaesthesiol Scand 2011;55:694-9.
P.63 掲載の参考文献
1) Schuller PJ, Newell S, Strickland PA, et al. Response of bispectral index to neuromuscular block in awake volunteers. Br J Anaesth 2015;115:i95-103.
2) Dahaba AA, Bornemann H, Hopfgartner E, et al. Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia. Br J Anaesth 2012;108:602-6.
P.66 掲載の参考文献
1) Forbes AR, Cohen NH, Eger EI II. Pancuronium reduces halothane requirement in man. Anesth Analg 1979;58:497-9.
2) Schwatz AE, Navedo AT, Berman MF. Pancuronium increases the duration of electroencephalogram burst suppression in dogs anesthetized with isoflurane. Anesthesiology 1992;77:686-90.
3) Lanier WL, Milde JH, Michenfelder JD. Cerebral stimulation following succinylcholine in dogs. Anesthesiology 1986;64:551-9.
4) Lanier WL, Iaizzo PA, Milde JH, et al. The cerebral and systemic effects of movement in response to a noxious stimulus in lightly anesthetized dogs. Possible modulation of cerebral function by muscle afferents. Anesthesiology 1994;80:392-401.
5) Hobbs AJ, Bush GH, Downham DY. Peri-operative dreaming and awareness in children. Anaesthesia 1988;43:560-2.
P.67 掲載の参考文献
1) Stourac P, Adamus M, Seidlova D, et al. Low-dose or high-dose rocuronium reversed with neostigmine or sugammadex for cesarean delivery anesthesia:A randomized controlled noninferiority trial of time to tracheal intubation and extubation. Anesth Analg 2016;122:1536-45.
P.69 掲載の参考文献
1) Eissa S, Lim KS. Rocuronium and sugammadex as a novel management strategy in a patient with plasmacholinesterase deficiency presenting for electroconvulsive therapy. Anaesth Intensive Care 2011;39:764-5.
2) Konishi J, Suzuki T, Kondo Y, et al. Rocuronium and sugammadex used effectively for electroconvulsive therapy in a patient with Brugada syndrome. J ECT 2012;28:e21-2.
3) Turkkal DC, Gokmen N, Yildiz A, et al. A cross-over, post-electroconvulsive therapy comparison of clinical recovery from rocuronium versus succinylcholine. J Clin Anesth 2008;20:589-93.
4) Saricicek V, Sahin L, Bulbul F, et al. Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression? J ECT 2014;30:30-4.
5) Postaci A, Tiryaki C, Sacan O, et al. Rocuronium-sugammadex decreases the severity of postelectroconvulsive therapy agitation. J ECT 2013;29:e2-3.
P.71 掲載の参考文献
1) van Miert MM, Eastwood NB, Boyd AH, et al. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol 1997;44:139-44.
P.73 掲載の参考文献
1) Caldwell JE, Szenohradszky J, Segredo V, et al. The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium(ORG 7268)and its parent compound, vecuronium, in human volunteers. J Pharmacol Exp Ther 1994;270:1216-22.
2) Suzuki T, Mizutani H, Miyake E, et al. Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles. Acta Anaesthesiol Scand 2009;53:1336-40.
3) Matineau RJ, St. -Jean B, Kitts JB, et al. Cumulation and reversal with prolonged infusions of atracurium and vecuronium. Can J Anaesth 1992;39:670-6.
P.76 掲載の参考文献
1) Kajiura A, Nagata O, Sanui M. The pringle maneuver reduces the infusion rate of rocuronium required to maintain surgical muscle relaxation during hepatectomy. J Anesth 2018;32:409-13.
P.78 掲載の参考文献
1) Ono K, Manabe N, Ohta Y, et al. Influence of suxamethonium on the action of subsequently administered vecuronium and pancuronium. Br J Anaesth 1989;62:324-6.
P.80 掲載の参考文献
1) Fanelli V, Morita Y, Cappello P, et al. Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-α1. Anesthesiology 2016;124:132-40.
P.82 掲載の参考文献
1) Suzuki T, Mizutani H, Ishikawa K, et al. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. Br J Anaesth 2007;99:721-5.
P.86 掲載の参考文献
1) Zaric D, Axelsson K, Philipson L, et al. Blockade of the abdominal muscles measured by EMG during lumbar epidural analgesia with ropivacaine-A double-blind study. Acta Anaesthesiol Scand 1993;37:274-80.
2) Nydahl PA, Axelsson K, Philipson L, et al. Motor blockade and EMG recordings in epidural anaesthesia. A comparison between mepivacaine 2%, bupivacaine 0.5% and etidocaine 1.5%. Acta Anaesthesiol Scand 1989;33:597-604.
3) Suzuki T, Mizutani H, Ishikawa K, et al. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. Br J Anaesth 2007;99:721-5.
P.88 掲載の参考文献
1) Waud BE, Waud DR. Interaction of calcium and potassium with neuromuscular blocking agents. Br J Anaesth 1980;52:863-6.
2) Czarnetzki C, Tassonyi E, Lysakowski C, et al. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium. A randomized cotrolled trial. Anesthesiology 2014;121:59-67.
P.90 掲載の参考文献
1) Pavlin EG, Holle RH, Schoene RB. Recovery of airway protection compared with ventilation in humans after paralysis with curare. Anesthesiology 1989;70:381-5.
2) Mason LJ, Betts EK. Leg lift and maximum inspiratory force, clinical signs of neuromuscular blockade reversal in neonates and infants. Anesthesiology 1980;52:441-2.
3) Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 1997;86:765-71.
4) Murphy G, Szokol JW, Avram MJ, et al. Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. Anesth Analg 2013;117:133-41.
P.92 掲載の参考文献
1) Debaene B, Plaud B, Dilly MP, et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 2003;98:1042-8.
2) 鈴木孝浩. 筋弛緩薬の投与量はしっかりとしたモニタリングから-投与量への影響因子を探る-. 日臨麻会誌2010;30:759-63.
P.95 掲載の参考文献
1) Castro DS, Leao P, Borges S, et al. Sugammadex reduces postoperative pain after laparoscopic bariatric surgery:A randomized trial. Surg Laparosc Endsc Percutan Tech 2014;24:420-3.
P.98 掲載の参考文献
1) Sorgenfrei IF, Norrid K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex:A dose-finding and safety study. Anesthesiology 2006;104:667-74.
2) Duvaldestin P, Kuizenga K, Saldien V, et al. A randomized, dose-response study of sugammadex given for the reversal of deep rocuronium-or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth Analg 2010;110:74-82.
3) Kitajima O, Yamamoto M, Takagi S, et al. Potency estimation of sugammadex for the reversal of moderate rocuronium-induced neuromuscular block:A non-randomized dose-response study. J Anesth 2020;34:348-51.
P.100 掲載の参考文献
1) Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 2003;99:632-7.
P.102 掲載の参考文献
1) Peeters P, Passier P, Smeets J, et al. Sugammadex is cleared rapidly and primarily unchanged via renal excretion. Biopharm Drug Dispos 2011;32:159-67.
2) Cammu G, Van Vlem B, van den Heuvel M, et al. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth 2012;109:38290.
P.105 掲載の参考文献
1) Ulke ZS, Yavru A, Camci E, et al. Rocuronium and sugammadex in patients with myasthenia gravis undergoing thymectomy. Acta Anaesthesiol Scand 2013;57:745-8.
2) Kashiwai A, Suzuki T, Ogawa S. Sensitivity to rocuronium-induced neuromuscular block and reversibility with sugammadex in a patient with myotonic dystrophy. Case Report in Anesthesiology 2012;2012:107952.
3) Suzuki T, Kitajima O, Ueda K, et al. Reversibility of rocuronium-induced profound neuromuscular block with sugammadex in younger and older patients. Br J Anaesth 2011;106:823-6.
4) 山本聡美, 山本悠介, 近藤裕子ほか. 病的肥満を伴う脊髄性筋萎縮症III型妊婦におけるロクロニウムとスガマデクスの使用経験. 日臨麻会誌2015;35:311-4.
5) Yoshida F, Suzuki T, Kashiwai A, et al. Correlation between cardiac output and reversibility of rocuronium-induced moderate neuromuscular block with sugammadex. Acta Anaesthesiol Scand 2012;56:83-7.
6) Suzuki T, Nameki K, Shimizu H, et al. Efficacy of rocuronium and sugammadex in a patient with dermatomyositis. Br J Anaesth 2012;108:703.
7) Cammu G, Coart D, De Graeve, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex in heart failure patients:A prospective observational study. Acta Anaesthesiol Belg 2012;63:69-73.
8) Panhuizen IF, Gold SJ, Buerkle C, et al. Efficacy, safety and pharmacokinetics of sugammadex 4mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. Br J Anaesth 2015;114:777-84.
9) Czarnetzki C, Tassonyi E, Lysakowski C, et al. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium. A randomized controlled trial. Anesthesiology 2014;121:59-67.
10) Zwiers A, van den Heuvel M, Smeets J, et al. Assessment of the potential for displacement interactions with sugammadex:A pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig 2011;31:101-11.
11) Rezonja K, Sostaric M, Vidmar G, et al. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells. Anesth Analg 2014;118:755-63.
12) Gulec E, Biricik E, Turktan M, et al. The effect of intravenous dexamethasone on sugammadex reversal time in children undergoing adenotonsillectomy. Anesth Analg 2016;122:1147-52.
13) Buonanno P, Laiola A, Palumbo C, et al. Dexamethasone does not inhibit sugammadex reversal after rocuronium-induced neuromuscular block. Anesth Analg 2016;122:1826-30.
P.107 掲載の参考文献
1) De Kam PJ, Grobara P, Prohn M, et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther 2014;52:227-36.
2) Rahe-Meyer N, Fennema H, Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology 2014;121:969-77.
3) Peeters PAM, van den Heuvel MW, van Heumen E, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses(up to 96mg/kg)in healthy adult subjects. A randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig 2010;30:867-74.
P.110 掲載の参考文献
1) Malinovsky JM, Decagny S, Wessel F, et al. Systematic follow-up increases incidence of anaphylaxis during adverse reactions in anesthetized patients. Acta Anaesthesiol Scand 2008;52:175-81.
2) Ho G, Clarke RC, Sadleir PHM, et al. The first case report of anaphylaxis caused by the inclusion complex of rocuronium and sugammadex. A A Case Reports 2016;7:190-2.
3) Neuman MJ, Goel P. An anesthesiologist with an allergy to multiple neuromuscular blocking drugs:A new occupational hazard. Anesth Analg 2010;110:601-2.
P.116 掲載の参考文献
2) Yip PC, Hannam JA, Cameron AJD, et al. Incidence of residual neuromuscular blockade in a postanaesthetic care unit. Anaesth Intensive Care 2010;38:91-5.
3) Eriksson LI, Lennmarken C, Johnson A. Attenuated ventilatory response to hypoxaemia at vecuronium-induced partial neuromuscular block. Acta Anaesthesiol Scand 1992;36:710-5.
4) Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans:Simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology 1997;87:1035-43.
5) Murphy G, Szokol JW, Avram MJ, et al. Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. Anesth Analg 2013;117:133-41.
6) Berg H, Roed J, Viby-Mogensen J, et al. Residual neuromuscular block is a risk factor for postoperative pulmonary complications. A prospective, randomised, and blinded study of postoperative pulmonary complications after atracurium, vecuronium and pancuronium. Acta Anaesthesiol Scand 1997;41:1095-103.
P.118 掲載の参考文献
1) Broens SJL, Boon M, Martini CH, et al. Reversal of partial neuromuscular block and the ventilator response to hypoxia. Anesthesiology 2019;131:467-76.
P.122 掲載の参考文献
1) Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg 1999;89:333-9.
2) Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. Anesth Analg 2013;117:345-51.
3) Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade:A randomized, controlled study. Br J Anaesth 2015;115:743-51.
P.125 掲載の参考文献
1) Kent NB, Liang SS, Phillips S, et al. Therapeutic doses of neostigmine, depolarizing neuromuscular blockade and muscle weakness in awake volunteers:A double-blind, placebo-controlled, randomised volunteer study. Anaesthesia 2018;73:1079-89.
2) Cammu G, Schepens T, De Neve N, et al. Diaphragmatic and intercostal electromyographic activity during neostigmine, sugammadex and neostigmine-sugammadex-enhanced recovery after neuromuscular blockade. A randomized controlled volunteer study. Eur J Anaesthesiol 2017;34:8-15.
P.127 掲載の参考文献
1) Vymazal T, Krecmerova M, Bicek V, et al. Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery-A series of 117 cases. Ther Clin Risk Manag 2015;11:1593-6.
2) Mouri H, Jo T, Matsui H, et al. Effect of sugammadex on postoperative myasthenic crisis in myasthenia gravis patients:Propensity score analysis of a Japanese nationwide database. Anesth Analg 2020;130:367-73.
3) Fujimoto M, Terasaki S, Nishi M, et al. Response to rocuronium and its determinants in patients with myasthesia gravis. A case-control study. Eur J Anaesthesiol 2015;32:1-9.
P.130 掲載の参考文献
1) Forbes AR, Cohen NH, Eger II EI. Pancuronium reduces halothane requirement in man. Anesth Analg 1979;58:497-9.
2) Lanier WL, Laizzo PA, Milde JH, et al. The cerebral and systemic effects of movement in response to a noxious stimulus in lightly anesthetized dogs. Possible modulation of cerebral function by muscle afferents. Anesthesiology 1994;80:392-401.
3) Oh CS, Rhee KY, Yoon TG, et al. Postoperative delirium in elderly patients undergoing hip fracture surgery in the sugammadex era:A retrospective study. BioMed Research International 2016;Article ID 1054597.
P.133 掲載の参考文献
1) Cammu G, de Kam PJ, De Graeve K, et al. Repeat dosing of rocuronium 1.2mg kg-1 after reversal of neuromuscular block by sugammadex 4.0mg kg-1 in anaesthetized healthy volunteers:A modelling-based pilot study. Br J Anaesth 2010;105:487-92.
2) Iwasaki H, Sasakawa T, Takahoko K, et al. A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal. J Anesth 2016;30:534-7.
P.135 掲載の参考文献
1) Fawcett WJ, Stone JP. Recurarization in the recovery room following the use of magnesium sulfate. Br J Anaesth 2003;91:435-8.
P.137 掲載の参考文献
1) Ono K, Nagano O, Ohata Y, et al. Neuromuscular effects of respiratory and metabolic acid-base changes in vitro with and without nondepolarizing muscle relaxants. Anesthesiology 1990;73:710-6.
P.140 掲載の参考文献
1) Lee D, Johnson DL. Effect of d-tubocurarine and anaesthesia upon cardiac output in normal and histamine-depleted dogs. Can Anaesth Soc J 1971;18:157-65.
P.145 掲載の参考文献
1) Arain SR, Kern S, Ficke DJ, et al. Variability of duration of action of neuromuscular-blocking drugs in elderly patients. Acta Anaesthesiol Scand 2005;49:312-5.
2) Naguib M, Samarkandi AH, Bakhamees HS, et al. Histamine-release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 1995;75:588-92.
P.147 掲載の参考文献
1) Heerdt PM, Malhotra JK, Pan BY, et al. Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. Anesthesiology 2010;112:9106.
2) Haerter F, Simons JC, Foerster U, et al. Comparative effectiveness of calabadion and sugammadex to reverse non-depolarizing neuromuscular-blocking agents. Anesthesiology 2015;123:1337-49.
II モニター編
P.154 掲載の参考文献
1) Claudius C, Skovgaard LT, Viby-Mogensen J. Arm-to-arm variation when evaluating neuromuscular block:An analysis of the precision and the bias and agreement between arms when using mechanomyography or acceleromyography. Br J Anaesth 2010;105:310-7.
2) Merle JC, Jurczyk M, D'Honneur G, et al. Onset of neuromuscular block is the same if the ipsilateral or contralateral limb to the injection site is used for monitoring. Br J Anaesth 1995;74:333-4.
P.156 掲載の参考文献
1) Brull SJ, Silverman DG. Pulse width, stimulus intensity, electrode placement, and polarity during assessment of neuromuscular block. Anesthesiology 1995;83:702-9.
P.158 掲載の参考文献
1) Lee C, Katz RL. Fade of neutrally evoked compound electromyogram during neuromuscular block by d-tubocurarine. Anesth Analg 1977;56:271-5.
P.174 掲載の参考文献
1) Suzuki T, Fukano N, Kitajima O, et al. Normalization of acceleromyographic train-of-four ratio by baseline value for detecting residual neuromuscular block. Br J Anaesth 2006;96:44-7.
P.178 掲載の参考文献
1) Suzuki T, Kitajima O, Watanabe A, et al. Duration of vecuronium-induced neuromuscular block can be predicted by change of skin temperature over the thenar muscles. J Anesth 2004;18:172-6.
P.182 掲載の参考文献
1) Suzuki T, Mizutani H, Miyake E, et al. Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles. Acta Anaesthesiol Scand 2009;53:1336-40.
P.185 掲載の参考文献
1) Eikermann M, Peters J. Nerve stimulation at 0.15Hz when compared to 0.1Hz speeds the onset of action of cisatracurium and rocuronium. Acta Anaesthesiol Scand 2000;44:170-4.
2) Symington MJ, McCoy EP, Mirakhur RK, et al. Duration of stabilization of control responses affects the onset and duration of action of rocuronium but not suxamethonium. Eur J Anaesth 1996;13:377-80.
3) Cooper RA, Mirakhur RK, Elliott P, et al. Estimation of the potency of ORG 9426 using two different modes of nerve stimulation. Can J Anesth 1992;39:139-42.
P.188 掲載の参考文献
1) Viby-Mogensen J, Howardy-Hansen P, Chraemmer-Jorgensen B, et al. Posttetanic count (PTC):A new method of evaluating an intense nondepolarizing neuromuscular blockade. Anesthesiology 1981;55:458-61.
2) Baykara N, Woelfel S, Fine GF, et al. Predicting recovery from deep neuromuscular block by rocuronium in children and adults. J Clin Anesth 2002;14:214-7.
3) Werba A, Klezi M, Schramm W, et al. The level of neuromuscular block needed to suppress diaphragmatic movement during tracheal suction in patients with raised intracranial pressure:A study with vecuronium and atracurium. Anaesthesia 1993;48:301-3.
4) Howardy-Hansen P, Viby-Mogensen J, Gottschau A, et al. Tactile evaluation of the posttetanic count(PTC). Anesthesiology 1984;60:372-4.
5) Brull A, Silverman DG. Tetanus-induced changes in apparent recovery after bolus doses of atracurium or vecuronium. Anesthesiology 1992;77:642-5.
P.190 掲載の参考文献
1) Viby-Mogensen J, Jensen NH, Engbaek J, et al. Tactile and visual evaluation of the response to trainof-four nerve stimulation. Anesthesiology 1985;63:440-3.
2) Drenck NE, Ueda N, Olsen NV, et al. Manual evaluation of residual curarization using double burst stimulation:A comparison with train-of-four. Anesthesiology 1989;70:578-81.
P.194 掲載の参考文献
1) Ali HH, Wilson RS, Savarese JJ, et al. The effect of tubocurarine on indirectly elicited train-of-four muscle response and respiratory measurements in humans. Br J Anaesth 1975;47:570-4.
2) Eriksson LI, Lennmarken C, Wyon N, et al. Attenuated ventilator response to hypoxemia at vecuronium-induced partial neuromuscular block. Acta Anaesthesiol Scand 1992;36:710-5.
3) Eriksson LI, Sundman E, Olsson R, et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans. Simultaneous videomanometry and mechanomyography of awake human volunteer. Anesthesiology 1997;87:1035-43.
P.196 掲載の参考文献
1) Engbaek J, Ostergaard D, Viby-Mogensen J. Double burst stimulation (DBS):A new pattern of nerve stimulation to identify residual neuromuscular block. Br J Anaesth 1989;62:274-8.
2) Drenck NE, Ueda N, Olsen NV, et al. Manual evaluation of residual curarization using double burst stimulation:A comparison with train-of-four. Anesthesiology 1989;70:578-81.
3) Ueda N, Muteki T, Tsuda H, et al. Determining the optimal time for endotracheal intubation during onset of neuromuscular blockade. Eur J Anaesthesiol 1993;10:3-8.
P.201 掲載の参考文献
1) Fuchs-Buder T, Claudius C, Skovgaard LT, et al. Good clinical research practice in pharmacodynamics studies of neuromuscular blocking agents II:The Stockholm revision. Acta Anaesthesiol Scand 2007;51:789-808.
P.207 掲載の参考文献
1) Yamamoto S, Yamamoto Y, Kitajima O, et al. Reversal of neuromuscular block with sugammadex:A comparison of the corrugator supercilii and adductor pollicis muscles in a randomized dose-response study. Acta Anaesthesiol Scand 2015;59:892-901.
P.210 掲載の参考文献
1) Yamamoto M, Suzuki T. Neuromuscular blockade at the orbicularis oculi muscle in a patient with myasthenia gravis. J Clin Monit Comput. 2019 Nov 15. doi:10.1007/s10877-019-00422-9. Online ahead of print.
最近チェックした商品履歴
Loading...